Breaking News
FDA has accepted a supplemental new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years.
New research has found that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine.
The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
BioTrending
- By Keith Berman, MPH, MBA
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
- By Trudie Mitschang
As chronic disease and aging populations drive healthcare costs higher, value-based care offers a sustainable path forward — rewarding providers for better outcomes, improved patient experiences and greater cost-efficiency.
- By Diane L.M. Cook
With a pending shortage of cardiologists, there is a growing need for remote cardiac monitoring, and now, three FDA-cleared products are transforming how this care is provided.
- By Lee Warren
The use of AI is growing at a brisk rate as healthcare professionals realize its potential as an indispensable partner in treating patients.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
